TCGA-D8-A27E-01A-11R-A16F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.320
- PROTEIN_SECRETION+0.260
- HEME_METABOLISM+0.250
- ADIPOGENESIS+0.240
- PANCREAS_BETA_CELLS+0.230
- BILE_ACID_METABOLISM+0.210
- FATTY_ACID_METABOLISM+0.140
- ANDROGEN_RESPONSE+0.110
- PEROXISOME+0.070
- ESTROGEN_RESPONSE_EARLY+0.060
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- APICAL_SURFACE-0.380
- APICAL_JUNCTION-0.370
- DNA_REPAIR-0.350
- MYC_TARGETS_V1-0.350
- WNT_BETA_CATENIN_SIGNALING-0.350
- NOTCH_SIGNALING-0.330
- MYC_TARGETS_V2-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296076 | — | cohortA1 | 0.858 |
| 2 | C3L-03721 | — | cohortA2 | 0.852 |
| 3 | SRR975556 | — | — | 0.839 |
| 4 | SRR12202450 | — | — | 0.836 |
| 5 | TCGA-A2-A4S0-01A-21R-A266-07 | — | B | 0.824 |
| 6 | SRR661445 | GTEX | — | 0.818 |
| 7 | MDT-AP-0854 | Med | Medulloblastoma | 0.816 |
| 8 | SRR8613744 | — | F | 0.815 |
| 9 | 20070161.TNBC | — | F | 0.808 |
| 10 | SRR2016961 | — | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |